sulfatase modifying factor 1
Zuletzt aktualisiert 18. Aug 2020
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Der SUMF1 gene provides instructions for making an enzyme called formylglycine-generating enzyme (FGE). This enzyme is found in a cell structure called the endoplasmic reticulum, which is involved in protein processing and transport. The FGE enzyme modifies other enzymes called sulfatases, which aid in breaking down substances that contain chemical groups known as sulfates. These substances include a variety of sugars, fats, and hormones. Specifically, FGE converts a protein building block (amino acid) within sulfatases called cysteine into a molecule called C-alpha-formylglycine.
Normal function
Der SUMF1 gene provides instructions for making an enzyme called formylglycine-generating enzyme (FGE). This enzyme is found in a cell structure called the endoplasmic reticulum, which is involved in protein processing and transport. The FGE enzyme modifies other enzymes called sulfatases, which aid in breaking down substances that contain chemical groups known as sulfates. These substances include a variety of sugars, fats, and hormones. Specifically, FGE converts a protein building block (amino acid) within sulfatases called cysteine into a molecule called C-alpha-formylglycine.
Conditions referring to this gene or chromosome
Other names
AAPA3037
C-alpha-formylglycine-generating enzyme 1
FGE
FGly-generating enzyme
sulfatase-modifying factor 1
UNQ3037
Related patient information and medicines

Patient information leaflet
Antirheumatika, die den Krankheitsverlauf beeinflussen
Antirheumatika, die den Krankheitsverlauf beeinflussen (DMARDs) are medicines that are normally prescribed as soon as rheumatoid Arthritis (RA) is diagnosed, in order to reduce damage to the joints. Disease-modifizierende Antirheumatika (DMARDs) are a group of medicines that are used to ease the Symptome von rheumatoide Arthritis (RA) Rheumatoid Arthritis and reduce.

Patient information leaflet
Reaktive Arthritis
... If symptoms continue for more than a few months, or if other treatments have not worked, you may be advised to take a disease-modifying medicine Disease-modifying antirheumatic drugs. These are sometimes called disease-modifying antirheumatic drugs (DMARDs). This aims to reduce the damaging effect on the joints. There are several - for.

Patient information leaflet
Psoriasis-Arthritis
Psoriasis-Arthritis is a particular type von Arthritis that develops in some people who also have psoriasis. Arthritis Arthritis means inflammation of the joints. They work by blocking the effects of chemicals involved in causing joint inflammation. Sulfasalazine Sulfasalazine and methotrexate Methotrexate are the most commonly used DMARDs for.

Patient information leaflet
Rheumatoide Arthritis
Rheumatoid arthritis causes inflammation, pain, and swelling of joints. Rheumatoid Arthritis treatment Standards of care Sie should expect The National Institute for Health and Care Excellence (NICE) has published quality standards on the standard of care that should be offered to every adult over 16 who has RA. ...Ds) Disease-modifyingDMARDs.

Patient information leaflet
Primär sklerosierende Cholangitis
Primäre sklerosierende Cholangitis is an uncommon condition affecting the bile ducts and liver. Inflammation and scarring of the bile ducts can lead to liver damage and cirrhosis - a condition where normal liver tissue is replaced by scar tissue (fibrosis). Different treatments are available to control symptoms that may develop and also to manage ....

Patient information leaflet
Juvenile idiopathische Arthritis
So, juvenile idiopathic arthritis (JIA) is a condition in which this Entzündung of one or more joints begins in children under the age of 16 years. ...e used to help reduce the effects of the disease Disease-modifyingDMARDs used for JIA include: Methotrexate Methotrexate Sulfasalazine Sulfasalazine Leflunomide Leflunomide tablets for arthritis.
Weiterführende Lektüre und Referenzen
- sulfatase modifying factor 1; MedlinePlus, National Library of Medicine.
- Annunziata I, Bouche V, Lombardi A, Settembre C, Ballabio A. Multiple sulfatase deficiency is due to hypomorphic mutations of the SUMF1 gene. Hum Mutat. 2007 Sep;28(9):928. doi: 10.1002/humu.9504.
- Cosma MP, Pepe S, Annunziata I, Newbold RF, Grompe M, Parenti G, Ballabio A. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell. 2003 May 16;113(4):445-56. doi: 10.1016/s0092-8674(03)00348-9.
- Cosma MP, Pepe S, Parenti G, Settembre C, Annunziata I, Wade-Martins R, Di Domenico C, Di Natale P, Mankad A, Cox B, Uziel G, Mancini GM, Zammarchi E, Donati MA, Kleijer WJ, Filocamo M, Carrozzo R, Carella M, Ballabio A. Molecular and functional analysis of SUMF1 mutations in multiple sulfatase deficiency. Hum Mutat. 2004 Jun;23(6):576-81. doi: 10.1002/humu.20040.
- Dierks T, Dickmanns A, Preusser-Kunze A, Schmidt B, Mariappan M, von Figura K, Ficner R, Rudolph MG. Molecular basis for multiple sulfatase deficiency and mechanism for formylglycine generation of the human formylglycine-generating enzyme. Cell. 2005 May 20;121(4):541-552. doi: 10.1016/j.cell.2005.03.001.
- Dierks T, Schmidt B, Borissenko LV, Peng J, Preusser A, Mariappan M, von Figura K. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell. 2003 May 16;113(4):435-44. doi: 10.1016/s0092-8674(03)00347-7.
- Schlotawa L, Ennemann EC, Radhakrishnan K, Schmidt B, Chakrapani A, Christen HJ, Moser H, Steinmann B, Dierks T, Gartner J. SUMF1 mutations affecting stability and activity of formylglycine generating enzyme predict clinical outcome in multiple sulfatase deficiency. Eur J Hum Genet. 2011 Mar;19(3):253-61. doi: 10.1038/ejhg.2010.219. Epub 2011 Jan 12.
- Schlotawa L, Radhakrishnan K, Baumgartner M, Schmid R, Schmidt B, Dierks T, Gartner J. Rapid degradation of an active formylglycine generating enzyme variant leads to a late infantile severe form of multiple sulfatase deficiency. Eur J Hum Genet. 2013 Sep;21(9):1020-3. doi: 10.1038/ejhg.2012.291. Epub 2013 Jan 16.
- Schlotawa L, Steinfeld R, von Figura K, Dierks T, Gartner J. Molecular analysis of SUMF1 mutations: stability and residual activity of mutant formylglycine-generating enzyme determine disease severity in multiple sulfatase deficiency. Hum Mutat. 2008 Jan;29(1):205. doi: 10.1002/humu.9515.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
18. Aug 2020 | Neueste Version
1 Jul 2014 | Ursprünglich veröffentlicht
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

